Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Therapeutic potential of chemokine receptor antagonists for liver disease.

Sahin H, Berres ML, Wasmuth HE.

Expert Rev Clin Pharmacol. 2011 Jul;4(4):503-13. doi: 10.1586/ecp.11.24. Review.

PMID:
22114859
2.

Chemokines as immune mediators of liver diseases related to the metabolic syndrome.

Berres ML, Nellen A, Wasmuth HE.

Dig Dis. 2010;28(1):192-6. doi: 10.1159/000282085. Epub 2010 May 7. Review.

PMID:
20460910
3.
4.

Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression.

Fischer FR, Santambrogio L, Luo Y, Berman MA, Hancock WW, Dorf ME.

J Neuroimmunol. 2000 Oct 2;110(1-2):195-208.

PMID:
11024550
5.

Chemokines in liver inflammation and fibrosis.

Wasmuth HE, Tacke F, Trautwein C.

Semin Liver Dis. 2010 Aug;30(3):215-25. doi: 10.1055/s-0030-1255351. Epub 2010 Jul 21. Review.

PMID:
20665374
6.

[Pathogenesis of liver fibrosis: modulation of stellate cells by chemokines].

Wasmuth HE, Weiskirchen R.

Z Gastroenterol. 2010 Jan;48(1):38-45. doi: 10.1055/s-0028-1109933. Epub 2010 Jan 13. Review. German.

PMID:
20072995
7.

Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.

Nomiyama H, Hieshima K, Nakayama T, Sakaguchi T, Fujisawa R, Tanase S, Nishiura H, Matsuno K, Takamori H, Tabira Y, Yamamoto T, Miura R, Yoshie O.

Int Immunol. 2001 Aug;13(8):1021-9.

PMID:
11470772
8.

Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines.

Cockwell P, Calderwood JW, Brooks CJ, Chakravorty SJ, Savage CO.

Nephrol Dial Transplant. 2002 May;17(5):734-44.

PMID:
11981057
9.

Endogenous ligand bias by chemokines: implications at the front lines of infection and leukocyte trafficking.

Zidar DA.

Endocr Metab Immune Disord Drug Targets. 2011 Jun;11(2):120-31. Review.

PMID:
21476969
10.

Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants.

Goddard S, Williams A, Morland C, Qin S, Gladue R, Hubscher SG, Adams DH.

Transplantation. 2001 Dec 27;72(12):1957-67.

PMID:
11773896
11.

Chemokine-directed immune cell infiltration in acute and chronic liver disease.

Karlmark KR, Wasmuth HE, Trautwein C, Tacke F.

Expert Rev Gastroenterol Hepatol. 2008 Apr;2(2):233-42. doi: 10.1586/17474124.2.2.233. Review.

PMID:
19072358
12.

Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics.

Wald O, Weiss ID, Galun E, Peled A.

Cytokine. 2007 Jul;39(1):50-62. Epub 2007 Jul 16. Review.

PMID:
17629707
13.

CCR1 antagonists for the treatment of autoimmune diseases.

Gladue RP, Zwillich SH, Clucas AT, Brown MF.

Curr Opin Investig Drugs. 2004 May;5(5):499-504. Review.

PMID:
15202722
14.

Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis.

Shahrara S, Amin MA, Woods JM, Haines GK, Koch AE.

Arthritis Rheum. 2003 Dec;48(12):3568-83.

15.

[Chemokine--possible new options for the treatment of multiple sclerosis].

Trebst C, Ransohoff RM, Windhagen A, Stangel M.

Nervenarzt. 2003 Oct;74(10):850-7. Review. German.

PMID:
14551688
16.

The strategy of blocking the chemokine system to combat disease.

Proudfoot AE, Power CA, Wells TN.

Immunol Rev. 2000 Oct;177:246-56. Review.

PMID:
11138781
19.

Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES.

Matsui M, Weaver J, Proudfoot AE, Wujek JR, Wei T, Richer E, Trapp BD, Rao A, Ransohoff RM.

J Neuroimmunol. 2002 Jul;128(1-2):16-22.

PMID:
12098506
20.

Supplemental Content

Support Center